Citigroup
IRD

Citigroup’s Opus Genetics IRD Stock Holding History

Citigroup’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-496
Closed -$997 – 6499
2025
Q4 		$997 Buy
496
+495
+49,500% +$1K ﹤0.01% 5545
2025
Q3 		$2 Buy
+1
New +$1 ﹤0.01% 6032
2022
Q2 		– Sell
-66
Closed – – 6747
2022
Q1 		$0 Buy
+66
New +$226 ﹤0.01% 6659
2016
Q1 		– Hold
0
– – – 7811
2015
Q4 		– Sell
-8
Closed -$1.7K – 7911
2015
Q3 		$2K Sell
8
-7
-47% -$1.9K ﹤0.01% 7060
2015
Q2 		$4K Hold
15
– – ﹤0.01% 6903
2015
Q1 		$5K Hold
15
– – ﹤0.01% 6728
2014
Q4 		$5K Hold
15
– – ﹤0.01% 6684
2014
Q3 		$6K Sell
15
-12
-44% -$4.32K ﹤0.01% 6507
2014
Q2 		$11K Sell
27
-4
-13% -$1.82K ﹤0.01% 6137
2014
Q1 		$16K Buy
31
+10
+48% +$5.41K ﹤0.01% 6146
2013
Q4 		$6K Buy
21
+6
+40% +$1.27K ﹤0.01% 6583
2013
Q3 		$3K Hold
15
– – ﹤0.01% 6541
2013
Q2 		$3K Buy
+15
New +$2.57K ﹤0.01% 6467

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Citigroup's IRD Position: Q1 2026 in Review

Citigroup sold out of Opus Genetics (IRD) in Q1 2026, closing a stake of 496 shares — an estimated $997 sold.

Citigroup first reported a position in IRD in Q2 2013 and held it in 13 quarters. The position peaked at $16K in Q1 2014. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Citigroup reported no remaining Opus Genetics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 496 Opus Genetics shares in Q1 2026, an estimated $997.
  • Citigroup first reported a position in Opus Genetics in Q2 2013 and held it in 13 quarters.
  • Citigroup's Opus Genetics position peaked at $16K in Q1 2014.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.